))
Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going
Manage episode 384366270 series 3381434
Innhold levert av ReachMD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av ReachMD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
CME credits: 0.50
Valid until: 14-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/targeting-her3-in-breast-and-lung-cancers-where-we-are-and-where-we-are-going/15054/
This CME-accredited podcast explores the rationale for targeting human epidermal growth factor receptor 3 (HER3) in non–small cell lung cancer (NSCLC) and breast cancer. It includes an in-depth discussion of the mechanism of action, safety, and efficacy of agents that are being investigated to target HER3. The latest results from clinical trials investigating monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates targeting HER3 will also be discussed.=
…
continue reading
Valid until: 14-05-2024
Claim your CME credit at https://reachmd.com/programs/cme/targeting-her3-in-breast-and-lung-cancers-where-we-are-and-where-we-are-going/15054/
This CME-accredited podcast explores the rationale for targeting human epidermal growth factor receptor 3 (HER3) in non–small cell lung cancer (NSCLC) and breast cancer. It includes an in-depth discussion of the mechanism of action, safety, and efficacy of agents that are being investigated to target HER3. The latest results from clinical trials investigating monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates targeting HER3 will also be discussed.=
657 episoder
Del
